1. Search Result
Search Result
Results for "

17 dmag hsp70 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

1603

Inhibitors & Agonists

2

Screening Libraries

5

Fluorescent Dye

10

Biochemical Assay Reagents

128

Peptides

35

Inhibitory Antibodies

134

Natural
Products

233

Recombinant Proteins

145

Isotope-Labeled Compounds

60

Antibodies

17

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1896

    HSP Infection Neurological Disease Cancer
    Hsp70-derived octapeptide is a conserved octapeptide of the C-terminal end of Hsp70, which physically interacts with tetratricopeptide repeat (TPR) motifs .
    <em>Hsp70</em>-derived octapeptide
  • HY-149637

    Sirtuin HSP Cancer
    HSP70/SIRT2-IN-1 (Compounds 2a) is a dual inhibitor for SIRT2 and HSP70, with IC50 of 17.3±2.0 μM for SIRT2. HSP70/SIRT2-IN-1 has antitumor activity .
    <em>HSP70</em>/SIRT2-IN-1
  • HY-18406

    HSP Cancer
    HSP70-IN-4 (Compound YM-01) is an Hsp70 inhibitor with an IC50 of 3.2 μM. HSP70-IN-4 is not BBB permeable .
    <em>HSP70</em>-IN-4
  • HY-149638

    Sirtuin HSP Cancer
    HSP70/SIRT2-IN-2 (Compounds 1a) is a dual inhibitor for SIRT2 and HSP70, with IC50 of 45.1±5.0 μM for SIRT2. HSP70/SIRT2-IN-2 has antitumor activity .
    <em>HSP70</em>/SIRT2-IN-2
  • HY-143400

    HSP Hedgehog Cancer
    HSP70-IN-3 is a potent HSP70 inhibitor (IC50s of 1.1 and 1.9 μM in ASZ001 and C3H10T1/2, respectively). HSP70-IN-3 has anti-Hh (Hedgehog signaling) activity and anti-proliferative activity and reduces expression of the oncogenic transcription factor GLI1 .
    <em>HSP70</em>-IN-3
  • HY-12622
    HSP70-IN-1
    1 Publications Verification

    HSP Cancer
    HSP70-IN-1 is a heat shock protein (HSP) inhibitor; inhibits the growth of Kasumi-1 cells with an IC50 of 2.3 μM.
    <em>HSP70</em>-IN-1
  • HY-10941
    VER-155008
    10+ Cited Publications

    HSP Autophagy Neurological Disease Cancer
    VER-155008 is an inhibitor of Hsp70, with IC50s of 0.5 μM, 2.6 μM, and 2.6 μM for Hsp70, Hsc70 and Grp7, respectively, and with a Kd of 0.3 μM for Hsp70.
    VER-155008
  • HY-107599

    JNK Apoptosis Neurological Disease
    AEG3482 is a potent antiapoptotic compound that inhibits Jun kinase (JNK) activity through induced expression of heat shock protein 70 (HSP70). AEG3482 directly binds HSP90, thereby facilitating HSF1-dependent expression of HSP70 and HSP25 .
    AEG3482
  • HY-117282
    JG-98
    5 Publications Verification

    HSP Apoptosis Cancer
    JG-98, an allosteric heat shock protein 70 (Hsp70) inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages .
    JG-98
  • HY-116683

    MAL2-11B

    HSP DNA/RNA Synthesis Infection Cancer
    116-9e (MAL2-11B) is a Hsp70 co-chaperone DNAJA1 inhibitor. 116-9e inhibits Simian Virus 40 (SV40) replication and DNA synthesis. 116-9e inhibits tumor antigen (TAg)’s endogenous ATPase activity and the TAg-mediated activation of Hsp70 .
    116-9e
  • HY-15098
    Apoptozole
    5+ Cited Publications

    Apoptosis Activator VII

    HSP Apoptosis Cancer
    Apoptozole (Apoptosis Activator VII) is an inhibitor of the ATPase domain of Hsc70 and Hsp70, with Kds of 0.21 and 0.14 μM, respectively, and can induce apoptosis.
    Apoptozole
  • HY-111002

    NSC375009

    HSP Others
    Displurigen (NSC375009) disrupts human embryonic stem cell pluripotency by targeting HSPA8. Displurigen inhibits ATPase activity of HSP70 (IC50 = 225 μM) .
    Displurigen
  • HY-120909

    HSP Apoptosis Cancer
    YK5 is a potent and selective Hsp70 inhibitor. YK5 selectively and tightly binds to the cytosolic Hsp70s in cancer cells. YK5 has biological activity partly by interfering with the formation of active oncogenic Hsp70/Hsp90/client protein complexes .
    YK5
  • HY-138820

    HSP Neurological Disease
    SW02 is a potent activator of ATPase activity of Hsp70, with an EC50 of 150 μM. SW02 leads to accumulation of both total tau and phosphorylated tau (pTau) .
    SW02
  • HY-18669
    ML346
    3 Publications Verification

    HSP Cancer
    ML346 is an activator of Hsp70 expression and HSF-1 activity, with an EC50 of 4.6 μM for Hsp70. ML346 restores protein folding in conformational disease models, without significant cytotoxicity or lack of specificity. ML346 induces specific increases in genes and protein effectors of the heat shock response (HSR), including chaperones such as Hsp70, Hsp40, and Hsp27 .
    ML346
  • HY-139144

    Sirtuin HSP Neurological Disease Cancer
    YM-08 (Compounds 7a) is a brain-penetrant inhibitors of SIRT2,with the IC50 of 19.9 μM. YM-08 also is inhibitor of Hsp70 .
    YM-08
  • HY-10940
    Pifithrin-μ
    5+ Cited Publications

    PFTμ; 2-Phenylethynesulfonamide

    MDM-2/p53 HSP Autophagy Neurological Disease Cancer
    Pifithrin-μ is an inhibitor of p53 and HSP70, with antitumor and neuroprotective activity.
    Pifithrin-μ
  • HY-148745

    HSP Cancer
    JG-258 is an inactive negative control for Hsp70 inhibitors .
    JG-258
  • HY-162008

    HSP Bcl-2 Family Cancer
    S1g-10 is a Hsp70/Bim inhibitor, and shows antitumor activity in chronic myeloid leukemia cells .
    S1g-10
  • HY-10389
    Alvespimycin
    10+ Cited Publications

    17-dmag; NSC 707545

    HSP Cancer
    Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 ± 29 nM.
    Alvespimycin
  • HY-124805

    HSP Cancer
    MAL3-101 is a potent HSP70 allosteric inhibitor. MAL3-101 inhibits HSP70 ATPase activity by blocking Hsp40 co-chaperone interaction. MAL3-101 can be used for researching muscle invasive bladder cancer (MIBC) .
    MAL3-101
  • HY-100110
    KNK437
    2 Publications Verification

    Heat Shock Protein Inhibitor I

    HSP Cancer
    KNK437 is a HSP inhibitor, and inhibits the induction of HSP105, HSP70, and HSP40.
    KNK437
  • HY-12024
    Alvespimycin hydrochloride
    10+ Cited Publications

    17-dmag hydrochloride; KOS-1022; BMS 826476

    HSP Apoptosis Cancer
    Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of Hsp90, binding to Hsp90 with EC50 of 62±29 nM.
    Alvespimycin hydrochloride
  • HY-N0754

    HSP Inflammation/Immunology
    Eupalinolide A, isolated from Eupatorium lindleyanum, induces the expression of HSP70 via the activation of HSF1 by inhibiting the interaction between HSF1 and HSP90 .
    Eupalinolide A
  • HY-145559

    KU-596

    HSP Metabolic Disease
    Cemdomespib (KU-596) is a highly bioavailable second-generation Hsp90 modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy. Cemdomespib induces Hsp70 levels and manifest neuroprotective activity through induction of the heat shock response .
    Cemdomespib
  • HY-18619
    YL-109
    1 Publications Verification

    Aryl Hydrocarbon Receptor Cancer
    YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness .
    YL-109
  • HY-124611

    HSP Cancer
    JG-231 is an analogue of JG-98 with anticancer effects. JG-231 inhibits the interaction of Hsp70-BAG3. JG-231 inhibits MDA-MB-231 heterograft tumor models of triple negative breast cancer (TNBC) .
    JG-231
  • HY-17504B
    Rosuvastatin Sodium
    5+ Cited Publications

    ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium

    HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial Cardiovascular Disease Metabolic Disease
    Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Sodium
  • HY-101712
    TRC051384
    3 Publications Verification

    HSP Neurological Disease
    TRC051384 is a potent inducer of heat shock protein 70 (HSP70). TRC051384 exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 can be used for the research of ischemic stroke .
    TRC051384
  • HY-124109

    HSP Cardiovascular Disease Neurological Disease
    TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke .
    TRC051384 hydrochloride
  • HY-114664

    HSP Infection Cancer
    KNK423 is a specific heat shock protein (HSP) synthesis inhibitor. KNK423 improves the efficiency of Amphotericin B in inhibiting resistant Aspergillus terreus by blocking HSP70. KNK423 can be used in cancer and bacterial infection research .
    KNK423
  • HY-153202

    MDM-2/p53 Apoptosis Cancer
    SLMP53-2 is a mutant p53 reactivator. SLMP53-2 restores wild-type-like conformation and DNA-binding ability of mutp53-Y220C by enhancing its interaction with the Hsp70, leading to the reestablishment of p53 transcriptional activity. SLMP53-2 can induce cell cycle arrest, apoptosis and endoplasmic reticulum (ER) stress. SLMP53-2 exhibits antitumor activity .
    SLMP53-2
  • HY-17504
    Rosuvastatin Calcium
    5+ Cited Publications

    Rosuvastatin hemicalcium; ZD 4522 Calcium

    HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Calcium
  • HY-17504D

    HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Cardiovascular Disease Metabolic Disease
    (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    (3S,5R)-Rosuvastatin
  • HY-17504C

    HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Cardiovascular Disease Metabolic Disease
    (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    (3R,5R)-Rosuvastatin
  • HY-115467
    MitoBloCK-10
    1 Publications Verification

    HSP Metabolic Disease
    MitoBloCK-10 (MB-10) is the first small molecule modulator to attenuate protein-associated motor (PAM) complex activity. MitoBloCK-10 (MB-10) inhibits Tim44 (C-terminal domain) binding to the precursor and to Hsp70 .
    MitoBloCK-10
  • HY-18399

    HSP NO Synthase Cancer
    YM-1 is a stable and soluble MKT-077 (HY-15096) analog and an orally active Hsp70 inhibitor. YM-1 induces cell death of HeLa cells and up-regulates the level of p53 and p21 proteins .
    YM-1
  • HY-126601

    Parasite HSP Infection
    Malonganenone A is an antimalarial marine alkaloid that disrupts the interaction between PfHsp70-x and Hsp40. Malonganenone A inhibits plasmodial and not human Hsp70 ATPase activity (Hsp40-stimulated), and hindered the aggregation suppression activity of PfHsp70-x .
    Malonganenone A
  • HY-17504A

    ZD 4522

    HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin
  • HY-118783

    (±)-2-Hexyl-4-pentynoic acid

    HDAC HSP Neurological Disease
    2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), valproic acid (VPA) derivative, exhibits potential roles of HDAC inhibition (IC50=13 μM) and HSP70 induction. Potent neuroprotective effects. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons . 2-Hexyl-4-pentynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    2-Hexyl-4-pentynoic acid
  • HY-101508

    Histone Methyltransferase Cancer
    GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC50 of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .
    GNA002
  • HY-155580

    Monoamine Oxidase HSP Cancer
    MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape [1].
    MAO A/<em>HSP</em>90-IN-2
  • HY-17504R
    Rosuvastatin Calcium (Standard)
    3 Publications Verification

    Rosuvastatin hemicalcium (Standard); ZD 4522 Calcium (Standard)

    HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin (Calcium) (Standard) is the analytical standard of Rosuvastatin (Calcium). This product is intended for research and analytical applications. Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Calcium (Standard)
  • HY-146915S

    Isotope-Labeled Compounds Others
    17:0-17:1-17:0 TG-d5 is deuterium labeled 17:0-17:1-17:0 TG.
    <em>17</em>:0-<em>17</em>:1-<em>17</em>:0 TG-d5
  • HY-B0891
    17α-Hydroxyprogesterone
    2 Publications Verification

    17-Hydroxyprogesterone; 17-OHP

    17α-Hydroxyprogesterone (17-Hydroxyprogesterone) is an endogenous progesterone that serves as a chemical intermediate in the biosynthesis of other steroid hormones, including glucocorticoids, androgens, and estrogens.
    <em>17</em>α-Hydroxyprogesterone
  • HY-136239
    Beclomethasone 17-propionate
    1 Publications Verification

    Beclomethasone-17-monopropionate; 17-BMP

    Glucocorticoid Receptor Drug Metabolite Inflammation/Immunology
    Beclomethasone 17-propionate (Beclomethasone-17-monopropionate), an active metabolite of Beclomethasone dipropionate (HY-13571), is a glucocorticoid receptor (GR) agonist. Beclomethasone 17-propionate exhibits greater affinity for GR than Beclomethasone dipropionate. Beclomethasone 17-propionate effectively suppresses cytokine production in chronic obstructive pulmonary disease (COPD) lung macrophages .
    Beclomethasone <em>17</em>-propionate
  • HY-B1265

    Cortisol 17-valerate

    Others Others
    Hydrocortisone 17-valerate (Cortisol 17-valerate) is a thiazolidine compound .
    Hydrocortisone <em>17</em>-valerate
  • HY-161218

    17β-HSD Metabolic Disease
    HSD17B13-IN-17 (compound 9) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of < 0.1 μM and? < 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-17? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .
    HSD<em>17</em>B13-IN-<em>17</em>
  • HY-B0891R

    17-Hydroxyprogesterone(Standard); 17-OHP (Standard)

    Progesterone Receptor Endogenous Metabolite Others
    17α-Hydroxyprogesterone (Standard) is the analytical standard of 17α-Hydroxyprogesterone. This product is intended for research and analytical applications.
    <em>17</em>α-Hydroxyprogesterone (Standard)
  • HY-120255

    17(R)-HDoHE

    Others Inflammation/Immunology
    17(R)-HDHA (17(R)-HDoHE) is a pro-resolving mediator (SPM). 17(R)-HDHA enhances the differentiation of B cells toward the CD27(+)CD38(+) antibody-secreting cell phenotype, thereby strongly increasing IgM and IgG production by activated B cells. 17(R)-HDHA does not affect cell proliferation and is non-toxic to cells .
    <em>17</em>(R)-HDHA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: